1. Inicio
  2. Publicaciones
  3. Efficacy and Safety of Anakinra Plus Standard of Care for Patients With Severe COVID-19: A Randomized Phase 2/3 Clinical Trial.

Efficacy and Safety of Anakinra Plus Standard of Care for Patients With Severe COVID-19: A Randomized Phase 2/3 Clinical Trial.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Fanlo P
  • Gracia-Tello BDC
  • Fonseca Aizpuru E
  • Álvarez-Troncoso J
  • Gonzalez A
  • Prieto-González S
  • Freire M
  • Argibay AB
  • Pallarés L
  • Pérez M
  • Buján-Rivas S
  • Ibáñez B
  • GEAS-SEMI Group

Grupos

Abstract

COVID-19 pneumonia is often associated with hyperinflammation. The efficacy and safety of anakinra in treating patients with severe COVID-19 pneumonia and hyperinflammation are still unclear.

Datos de la publicación

ISSN/ISSNe:
2574-3805, 2574-3805

JAMA Network Open  AMER MEDICAL ASSOC

Tipo:
Article
Páginas:
237243-237243
PubMed:
37027155
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
4,031 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 22

Citas Recibidas en Scopus: 23

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • RECEPTOR BLOCKADE; CYTOKINE STORM; HYPERINFLAMMATION; INTERLEUKIN-1; PNEUMONIA

Campos de Estudio

Compartir